These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 28351398)

  • 21. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
    Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
    Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying CpG sites with different differential methylation frequencies in colorectal cancer tissues based on individualized differential methylation analysis.
    Yan H; He J; Guan Q; Cai H; Zhang L; Zheng W; Qi L; Zhang S; Liu H; Li H; Zhao W; Yang S; Guo Z
    Oncotarget; 2017 Jul; 8(29):47356-47364. PubMed ID: 28537885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
    Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
    Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
    Kim CH; Huh JW; Kim HR; Kim YJ
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
    Kawasaki T; Ohnishi M; Nosho K; Suemoto Y; Kirkner GJ; Meyerhardt JA; Fuchs CS; Ogino S
    Mod Pathol; 2008 Mar; 21(3):245-55. PubMed ID: 18204436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.
    Loh M; Liem N; Vaithilingam A; Lim PL; Sapari NS; Elahi E; Mok ZY; Cheng CL; Yan B; Pang B; Salto-Tellez M; Yong WP; Iacopetta B; Soong R
    BMC Gastroenterol; 2014 Mar; 14():55. PubMed ID: 24674026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers.
    Olaru AV; Cheng Y; Agarwal R; Yang J; David S; Abraham JM; Yu W; Kwon JH; Lazarev M; Brant SR; Marohn MR; Hutcheon DF; Harpaz N; Meltzer SJ; Mori Y
    Inflamm Bowel Dis; 2012 Apr; 18(4):641-8. PubMed ID: 21830278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple sporadic colorectal cancers display a unique methylation phenotype.
    Gonzalo V; Lozano JJ; Alonso-Espinaco V; Moreira L; Muñoz J; Pellisé M; Castellví-Bel S; Bessa X; Andreu M; Xicola RM; Llor X; Ruiz-Ponte C; Carracedo A; Jover R; Castells A; Balaguer F;
    PLoS One; 2014; 9(3):e91033. PubMed ID: 24643221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
    Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
    Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations.
    Kim YH; Lee HC; Kim SY; Yeom YI; Ryu KJ; Min BH; Kim DH; Son HJ; Rhee PL; Kim JJ; Rhee JC; Kim HC; Chun HK; Grady WM; Kim YS
    Ann Surg Oncol; 2011 Aug; 18(8):2338-47. PubMed ID: 21298349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
    Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer.
    Cheng YW; Pincas H; Bacolod MD; Schemmann G; Giardina SF; Huang J; Barral S; Idrees K; Khan SA; Zeng Z; Rosenberg S; Notterman DA; Ott J; Paty P; Barany F
    Clin Cancer Res; 2008 Oct; 14(19):6005-13. PubMed ID: 18829479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer.
    Gu S; Lin S; Ye D; Qian S; Jiang D; Zhang X; Li Q; Yang J; Ying X; Li Z; Tang M; Wang J; Jin M; Chen K
    Clin Epigenetics; 2019 Mar; 11(1):41. PubMed ID: 30846004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
    Jia M; Jansen L; Walter V; Tagscherer K; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
    Br J Cancer; 2016 Nov; 115(11):1359-1366. PubMed ID: 27811854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
    Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
    BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a CpG island methylator phenotype in adrenocortical carcinomas.
    Barreau O; Assié G; Wilmot-Roussel H; Ragazzon B; Baudry C; Perlemoine K; René-Corail F; Bertagna X; Dousset B; Hamzaoui N; Tissier F; de Reynies A; Bertherat J
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E174-84. PubMed ID: 23093492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.